Please login to the form below

Not currently logged in

UniQure edges closer to haemophilia B gene therapy OK

The candidate could free patients from regulator injections of FIX products

gene therapy

Dutch biotech UniQure has 12-week data for its haemophilia B gene therapy that backs up an earlier readout at six weeks, and keeps the pressure on rival Spark Therapeutics.

The updated results from a phase 2b study of AMT-061 showed sustained increases in Factor IX (FIX) clotting factor levels in all three patients dosed with the gene therapy, with an average boost of 38% and one patient showing a 51% rise. All three patients had severe haemophilia with FIX levels of less than 1% at enrolment.

UniQure thinks spontaneous bleeds decrease substantially when FIX activity is above 12% of normal, so with all three subjects in the study comfortably topping that level the results suggest AMT-061 should allow patients to reduce their use of recombinant FIX products. No patient suffered a bleed or needed FIX replacement therapy during the 12-week trial period, and importantly the results showed no sign that the efficacy of the therapy as tailing off.

UniQure has been vying to bring an effective haemophilia B therapy to market with Spark and partner Pfizer for some time, but suffered a setback when an earlier version of its candidate (AMT-060) failed to show enough potency in early testing. It subsequently swapped over to a new Factor IX construct – called Padua – that seems to have solved the potency issue. Spark/Pfizer’s SPK-9001 (fidanacogene elaparvovec) is also based on the Padua variant.

With AMT-061 and SPK-9001 both in phase 3 testing on the strength of proof-of-concept data, prospects are looking increasingly good of a one-shot therapy becoming available that could free patients from at least some of the regulator injections of FIX products they currently need to prevent breakthrough bleeding episodes.

According to the database, UniQure’s phase 3 trial – called HOPE-B – started recruiting its first patients last year and is due to start dosing this qyarter, with results expected in March 2020. Meanwhile, Pfizer and Spark’s phase 3 trial is due to read out in December of that year.

That gives UniQure a shot at being first to market, and the positive results sparked a 10% increase in its share price ahead of the weekend. Also in the hunt is UK-German biotech Freeline, which reported preliminary data from a phase 1/2 trial of its FLT180a candidate at last year’s American Society of Haematology (ASH) meeting

“We are extremely pleased with these updated data,” said UniQure’s chief medical officer Robert Gut (pictured below).

Robert Gut

“The study demonstrates AMT-061 has the potential to increase FIX activity into the normal range and continues to be very well tolerated, with no serious adverse events reported and no patients requiring any immunosuppression therapy,” he added.

Article by
Phil Taylor

11th February 2019

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....